Incentivising the development of new antibacterial treatments 2023

In 2021 and 2022, G7 Finance and Health Ministers committed to expedite implementation of existing antimicrobial resistance (AMR) strategies, to take additional steps to address antibiotic market failure, create economic conditions to preserve the effectiveness of essential existing antibiotics and ensure their access, strengthen AMR research and development (R&D), and bring novel antibacterials to market that address public health needs.

An initial progress report was prepared by the Global AMR R&D Hub and WHO for the G7 Finance and Health Ministers in May 2022, with a progress update requested for 2023. The present report is a response to this request providing an update on the financial landscape for developing new and innovative antibacterials, country-by-country progress on commitments and key areas for action in the next two years.